A stomach ulcer or peptic ulcer is a sore in the lining of your stomach or duodenum. The duodenum is the first part of your small intestine. If peptic ulcers are found in the stomach, they're called gastric ulcers. If they're found in the duodenum, they're called duodenal ulcers. You can have more than one ulcer.
Frailty is the medical term for becoming weaker or experiencing lower levels of activity/energy. Becoming frail as we age increases our risk for poor health, falls, disability, and other serious concerns. This can be especially true for older people facing surgery, up to half of whom are classified as frail.
Over the past couple of decades, the analytical technology and the clinical microbiology insight needed to create a breath test for infections has seen a considerable number of advances and there are now numerous research teams focused on evaluating patient breath as a diagnostic fluid for infectious diseases. Significant challenges still need to be overcome.
A West Australian team has found evidence that the stomach ulcer bacterium, Helicobacter pylori, is associated with a lower risk of multiple sclerosis (MS), bolstering evidence for the role of the ‘hygiene hypothesis’ in autoimmune disorders.
Stomach and bowel cancer, two of the most common cancers worldwide, could be treated with a class of medicines that are currently used to treat a blood disorder, a Melbourne research team has discovered.
We ring in the New Year with hopes of being healthy, wealthy, and wise. A new study led by San Diego State University School of Public Health research professor John W. Ayers suggests that from a public health standpoint, health and wealth may be connected.
Pain is defined by the sufferer’s experience. Pain may be severe because it is intense, frequent or sustained, and because it is distressing. The severity of pain is not simply due to what is going on in the joint, but is also affected by how the body processes the pain signals, and the context in which it is experienced.
Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced the introduction of Omeclamox-Pak®, a ten-day therapy of omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg) and amoxicillin capsules (500 mg) for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients.
Researchers have launched a major clinical trial to investigate whether eliminating a common stomach bug could help to make taking aspirin safer in some patients.
Medication errors are common in primary care but the number of mistakes could be reduced significantly if GPs introduced an in-house pharmacist-led intervention scheme.
Soon children could be vaccinated with bacteria mixed in milk and people in the developing world given unprecedented access to immunisations under a scheme proposed by an Australian Nobel laureate, Barry Marshall.
A study evaluating the level of platelet aggregation achieved after switching from Plavix (clopidogrel) 75 mg once-daily maintenance dosing plus aspirin to Effient(prasugrel) 10 mg once-daily maintenance dosing (MD) in patients with acute coronary syndrome (ACS) was published today in the Journal of the American College of Cardiology.
A VOA News editorial by the U.S. government reflects on last month's International AIDS Conference-AIDS 2010, including key advancements such as the vaginal microbicide gel found to offer women some protection against HIV infection as well discussions about funding for the fight against HIV/AIDS and how the "criminalization of drug abuse and persecution of homosexuals" in the world is compromising efforts to prevent the spread of the disease.
Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix® (clopidogrel), and commend the leading cardiovascular medical societies for providing perspective on the importance of genetic make-up and the variability in response of certain oral anti-platelet (OAP) therapy for patients with acute coronary syndrome (ACS) who are managed with angioplasty and stenting (known as PCI).
Researchers have identified cells in the immune system that react to the stomach ulcer bacterium Helicobacter pylori, one of the risk factors for the development of stomach cancer. This discovery could lead to faster diagnosis and treatment as well as a better prognosis for patients with stomach cancer, reveals a thesis from the University of Gothenburg, Sweden.
A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene. Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix® (clopidogrel) plus aspirin or Effient® (prasugrel) plus aspirin and managed with percutaneous coronary intervention (PCI) following an acute coronary syndrome (ACS) event.
Results from a health economic substudy of the TRITON-TIMI 38 clinical trial showed that among patients with acute coronary syndromes (ACS) managed with percutaneous coronary intervention (PCI), including stenting, treatment with Effient(®) (prasugrel) compared with branded clopidogrel (Plavix(®)) was more cost effective, and in most cases cost saving.
Effient® (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention (PCI) and a second one for patients with ST elevation myocardial infarction (STEMI), or severe heart attack.
Growing concerns about health has caused the scientific community to focus their interest on investigating functional foods which contribute to boosting the prevention and reduction of the risk of suffering from certain illnesses. The benefits of this product lies in its composition and, thus, its study, identification and subsequent extraction provides a useful tool which enables making high added-value products, given their high concentration of biologically active compounds.
A special protein in the lining of the stomach has been shown to be an important part of the body's defense against the stomach ulcer bacterium Helicobacter pylori in a new study from the Sahlgrenska Academy at the University of Gothenburg. The discovery may explain why the bacterium makes some people more ill than others.
A special protein in the lining of the stomach has been shown to be an important part of the body's defence against the stomach ulcer bacterium Helicobacter pylori in a new study from the Sahlgrenska Academy at the University of Gothenburg. The discovery may explain why the bacterium makes some people more ill than others.